Pacira BioSciences, Inc. (PCRX)

Market Cap	1.12B
Revenue (ttm)	705.85M
Net Income (ttm)	-127.46M
Shares Out	44.93M
EPS (ttm)	-2.81
PE Ratio	n/a
Forward PE	8.37
Dividend	n/a
Ex-Dividend Date	n/a

Volume	764,841
Open	24.82
Previous Close	24.81
Day's Range	24.82 - 25.15
52-Week Range	11.16 - 27.64
Beta	0.48
Analysts	Buy
Price Target	27.14 (+8.76%)
Earnings Date	Aug 5, 2025

About PCRX

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled dos...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 3, 2011
• Employees: 790
• Stock Exchange: NASDAQ
• Ticker Symbol: PCRX
• Website: https://www.pacira.com

Analyst Forecast

According to 7 analysts, the average rating for PCRX stock is "Buy." The 12-month stock price target is $27.14, which is an increase of 8.76% from the latest price.

Price Target

$27.14

(8.76% upside)

Analyst Consensus: Buy